K. OGASAWARA

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

Medicine, Oncology, Pharmacology +13

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 368 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

An NK1.1+ CD4+8- single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V beta family.

Hisashi Arase, Noriko Arase, K. OGASAWARA et al. · Proceedings of the National Academy of Sciences · 1992 · 262 citations

Life Sciences, Cell Biology, Immunology +14

Genetic Polymorphism of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) as a Risk Factor for Coronary Artery Disease

Hiroyuki Morita, Junichi Taguchi, Hiroki Kurihara et al. · Circulation · 1997 · 244 citations

Medicine, Genetics, Molecular Genetics +16